Home » Topics » BioWorld Science

BioWorld Science
RSS

Pfizer begins phase III study of PF-06801591 in high-risk nonmuscle invasive bladder cancer

Jan. 20, 2020

New compounds for Huntington's disease presented by PTC Therapeutics

Jan. 20, 2020

Meiji Seika Pharma describes new PDE4 inhibitors

Jan. 20, 2020

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Jan. 20, 2020

Single transcription factor enables chronic toxoplasma infection

Jan. 20, 2020

B cells help T cells succeed during checkpoint blockade

Jan. 20, 2020

Roche discloses new EGFR mutant inhibitors

Jan. 20, 2020

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Jan. 20, 2020

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Jan. 20, 2020

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

Jan. 20, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...